Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

NCT01206140 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

NIH

Sponsor class

Conditions

Recurrent Adult Soft Tissue Sarcoma
Stage III Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Selumetinib
DRUG: Temsirolimus

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]